Dominance in the Pharmaceutical Sector: An Overview of EU and National Case Law
The pharmaceutical sector is regularly under the scrutiny of competition authorities throughout Europe. In keeping with this trend, the past 18 months saw notable developments in pay-for-delay and excessive pricing cases, as well as on market definition and lifecycle management practices.
In this article, Dechert antitrust/competition attorneys Mélanie Thill-Tayara and Marion Provost describe the most recent developments in the sector, focusing on cases involving alleged abuses of dominant position.
Read "Dominance in the Pharmaceutical Sector: An Overview of EU and National Case Law."